<DOC>
	<DOCNO>NCT00642291</DOCNO>
	<brief_summary>To obtain safety efficacy data antiretroviral regimen contain emtricitabine HIV-1 infect pediatric subject . To determine emtricitabine concentration HIV-1 infect pediatric subject , necessary , refine dose emtricitabine achieve concentration comparable adult give 200 mg emtricitabine once-daily .</brief_summary>
	<brief_title>An Open-Label Study Emtricitabine Combination With Other Antiretroviral Agents HIV Infected Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Male female , age 3 24 month old 7 17 year old . ( Note : This criterion base subject 's age Baseline [ Day 1 ] . ) Documented evidence HIV1 infection . ( Note : HIV1 infection confirm two positive result obtain follow : age : HIV culture , HIV DNA PCR , plasma HIV RNA &gt; = 10,000 copies/mL ; age &gt; 4 week : neutralizable HIV p24 antigen ; age &gt; 18 month : license ELISA confirmatory Western blot . ) Body weight &gt; 2.5 kg ( &gt; 5.5 lb ) . Either ARTnaïve ARTexperienced , define : ARTnaïve : prior exposure ART ( exception &lt; = 56 cumulative day perinatal prophylactic treatment prevention maternaltochild transmission &lt; =6 week cumulative postnatal treatment ZDV monotherapy ) Screening plasma HIV1 RNA level &gt; = 5,000 copies/mL , child age &gt; = 7 year old , plasma HIV1 RNA &lt; = 600,000 copies/mL . OR ARTexperienced : previous treatment ART regimen ( ) include either lamivudine and/or NNRTI Screening plasma HIV1 RNA level &lt; = 600,000 copies/mL . Absolute CD4+ cell count &gt; = 200 cells/mm3 . Subjects whose parent legal guardian provide write informed consent participate study . Female subject childbearing potential ( i.e. , postpubertal ) negative serum beta human chorionic gonadotropin ( BetaHCG ) test Screening confirm negative urine pregnancy test Baseline , prior administration first dose emtricitabine . If sexually active and/or childbearing potential , subject ( male female ) willing use effective method contraception enrol study period least 1 month last dose emtricitabine Either subject subject 's parent legal guardian unable adhere child 's dose schedule protocol evaluation . Female subject pregnant breastfeeding . Treatment within 30 day prior Baseline investigational drug , agent , and/or vaccine ( exception investigational formulation approve drug ) unless prior approve investigator sponsor . Subjects require concomitant use : ( ) immunomodulators ( exception immune globulin colony stimulate factor ) ; ( b ) investigational drug , agent , and/or vaccine ( exception investigational formulation approve drug ; and/or ( c ) medication contraindicate protocolprescribed background medication , unless preapproved investigator sponsor . Subjects follow laboratory parameter Screening : 1 . Hemoglobin &gt; = Grade 3 toxicity ; 2 . Absolute neutrophil count ≥ Grade 2 toxicity ( assess without Neupogen [ filgrastim , GCSF ] ) ; 3 . Platelet count &gt; = Grade 2 toxicity ; 4 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; = Grade 2 toxicity ; ( Note : Rescreening NOT allow exclusionary AST ALT value , unless acute viral hepatitis document elevated ALT and/or AST demonstrate complete resolution exclusionary amylase lipase value . ) 5 . Serum creatinine &gt; = Grade 2 toxicity ; 6 . Total bilirubin &gt; = Grade 2 toxicity ( Gilbert 's syndrome ) ; 7 . Pancreatic amylase total amylase plus lipase &gt; = Grade 2 toxicity . ( Note : Rescreening NOT allow exclusionary amylase lipase value . ) Subjects clinical laboratory abnormality &gt; = Grade 3 toxicity ( use agespecific toxicity grade scale child &lt; 13 year old &gt; = 13 year old Screening unless preapproved investigator sponsor . Subjects &gt; = Grade 2 peripheral neuropathy Screening significant history peripheral neuropathy . Subjects malabsorption severe chronic diarrhea ( &gt; = Grade 2 ) within 30 day Screening , subject unable consume adequate oral intake ( defined inability eat &gt; = 1 meal ( ) day 3 feeding day young infant ) chronic nausea , emesis , abdominal esophageal discomfort . Subjects acute serious medical event within 30 day prior Screening unless preapproved investigator sponsor . ( Note : Acute treatment must complete &gt; = 14 day prior Baseline . ) Subjects AIDSdefining opportunistic infection within 12 month prior Screening . Life expectancy &lt; 12 month . Subjects currently treat active tuberculosis . Subjects history acute chronic ( clinical biological ) pancreatitis ( regardless serum amylase level ) . Any condition set circumstance , , opinion investigator sponsor , could interfere subject 's ability comply dose schedule complete study evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Emtricitabine</keyword>
	<keyword>Pediatric</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Treatment HIV-1</keyword>
</DOC>